Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea (SIX: BSLN) bags a US$2.5m milestone payment
Published by Arron Aatkar, PhD

Basilea has announced another milestone payment from its license partner Pfizer in the Asia Pacific region and China for strong Cresemba sales. Notably, the US$2.5m milestone payment is the first of 2025 in Asia Pacific and China, and twice the value of prior milestone payments from Pfizer for this region.

As a reminder, the license agreement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic countries), China and 16 countries in the Asia Pacific region.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.